Condition (MeSH)
Rhabdoid Tumor
ClinicalTrials.gov lists 115 trials for Rhabdoid Tumor or a narrower condition beneath it. National Cancer Institute (NCI) has the most among industry and government lead sponsors, with 21.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase (log scale)
115 of the 115 trials are tagged with Rhabdoid Tumor itself; the rest are tagged with a narrower condition beneath it.
When did Rhabdoid Tumor trials start? (29)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 3
- Not applicable
- Observational
Top of scale: 10
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 9 |
| 2025 | 4 |
| 2024 | 4 |
| 2023 | 4 |
| 2022 | 3 |
| 2021 | 6 |
| 2020 | 9 |
| 2019 | 7 |
| 2018 | 7 |
| 2017 | 10 |
Showing 10 of 29 earlier years.
No forecast is made for this condition: it averages 4.8 trial starts a year over the five years to September, under the 5 a year the method needs.
Prediction, not a registry value: median of 36 months from start to primary completion across 19 trials still running at the 2026-10-09 snapshot; registered median of 56 months across 77 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Rhabdoid Tumor trials in? (7)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 55 |
| Phase 1/2 | 8 |
| Phase 2 | 30 |
| Phase 3 | 3 |
| Not applicable | 5 |
| Observational | 12 |
| Expanded access | 2 |
How many Rhabdoid Tumor trials are recruiting? (8)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 3 |
| Recruiting | 20 |
| Active, not recruiting | 22 |
| Completed | 47 |
| Terminated | 14 |
Showing 5 of 8 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Rhabdoid Tumor trials? (4)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| National Cancer Institute (NCI) | 21 |
| Pediatric Brain Tumor Consortium | 9 |
| Children's Oncology Group | 8 |
| Epizyme, Inc. | 3 |
Which drugs are being tested for Rhabdoid Tumor? (3)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Cytoxan | 15 |
| Thiotepa | 7 |
| TOPOTECAN | 6 |
Interventions as named in the registry (12)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Etoposid | 14 |
| or carboplatin | 10 |
| SOC: Temozolomide | 10 |
| Filgrastime (G-CSF) | 9 |
| Vincristina | 8 |
Showing 5 of 12 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Rhabdoid Tumor trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Vomiting | 24 | 10 |
| Febrile neutropenia | 22 | 4 |
| Seizure | 22 | 10 |
| Disease progression | 19 | 10 |
| Respiratory failure | 18 | 8 |
Showing 5 of 10 adverse events.
Which publications cover Rhabdoid Tumor? (18)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Delta-24-RGD, an Oncolytic Adenovirus, Increases Survival and Promotes Proinflammatory Immune Landscape Remodeling in Models of AT/RT and CNS-PNET. | Clinical cancer research : an official journal of the American Association for Cancer Research | 2021 | Yes |
| Reply to S.A. Upadhyaya. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2020 | Yes |
| A Phase I Study of the CDK4/6 Inhibitor Ribociclib (LEE011) in Pediatric Patients with Malignant Rhabdoid Tumors, Neuroblastoma, and Other Solid Tumors. | Clinical cancer research : an official journal of the American Association for Cancer Research | 2017 | Yes |
| Diagnostic value of next-generation sequencing in an unusual sphenoid tumor. | The oncologist | 2014 | Yes |
| Synchronous perivesical and renal malignant rhabdoid tumor in a 9-year-old boy: a case report and review of literature. | Urology | 2013 | Yes |
Showing 5 of 18 publications.
Prevalence (9)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Rhabdoid tumor | Annual incidence | <1 / 1 000 000 | Europe | Not stated | Exact |
| Rhabdoid tumor | Point prevalence | Unknown | Worldwide | Not stated | Exact |
| Rhabdoid tumor | Cases families | Worldwide | Not stated | Exact | |
| Rhabdoid tumor | Annual incidence | <1 / 1 000 000 | Europe | Not stated | Exact |
| Rhabdoid tumor | Point prevalence | Unknown | Worldwide | Not stated | Unspecified |
Showing 5 of 9 prevalence observations.
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Rhabdoid tumor | 69077 | Exact | Orphadata Science knowledge files, Product 1 |
| Rhabdoid tumor | 69077 | Exact | Orphanet Rare Disease Ontology (ORDO) |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: sub-conditions in mesh.